结核分枝杆菌耐药机制和检测方法的研究进展

Abstract
Figure/Table
References (44)
Related Citation (15)

Download: PDF (750 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract This article reviews the mechanism and detection methods of drug resistance in Mycobacterium tuberculosis（MTB）. The mechanism of drug resistance is divided into intrinsic resistance mechanism of cell wall permeability reduction and efflux pump action and acquired resistance mechanism of target gene mutation. With the development of molecular biology techniques, mutations in target genes are considered to be the main mechanism of drug resistance for MTB. The main detection methods for drug resistance are phenotypic susceptibility testing and molecular susceptibility testing. The phenotypic assay method is used as the golden standard, but the detection period is long, while gene mutation detection can be completed within a few hours, so there is a better application prospect in the diagnosis of tuberculosis. In this paper, the mechanism and detection methods of drug resistance in MTB are reviewed in order to provide some reference for the development of rapid molecular diagnostic tools and anti-tuberculosis drugs.

Key words： Mycobacterium tuberculosis Drug resistance Detection method

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SONG Jing CHE Nanying

Cite this article:

SONG Jing CHE Nanying. Research progress of the mechanism of drug resistance and detection methods of Mycobacterium tuberculosis[J]. 中国医药导报, 2018, 15(29): 29-34.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I29/29

[1] World Health Organization. Global tuberculosis report 2017 [R]. Geneva：World Health Organization，2017.
[2] Almeida Da Silva PE，Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis：classical and new drugs [J]. J Antimicrob Chemother，2011，66（7）：1417-1430.
[3] Alderwick LJ，Harrison J，Lloyd GS，et al. The Mycobacterial cell wall--peptidoglycan and Arabinogalactan [J]. Cold Spring Harb Perspect Med，2015，5（8）：a021113.
[4] Kieser KJ，Baranowski C，Chao MC，et al. Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility [J]. Proc Natl Acad Sci U S A，2015，112（42）：13087-13092.
[5] Speer A，Rowland JL，Niederweis M. Mycobacterium tuberculosis is resistant to streptolydigin [J]. Tuberculosis（Edinb），2013，93（4）：401-404.
[6] Gupta AK，Reddy VP，Lavania M，et al. jefA（Rv2459），a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol [J]. Indian J Med Res，2010，132：176-188.
[7] Manson AL，Cohen KA，Abeel T，et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance [J]. Nat Genet，2017，49（3）：395-402.
[8] Sharma S，Tyagi JS. Mycobacterium tuberculosis DevR/DosR dormancy regulator activation mechanism：dispensability of phosphorylation，cooperativity and essentiality of α10 helix [J]. PLoS One，2016，11（8）：e0160723.
[9] Nandakumar M，Nathan C，Rhee KY. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis [J]. Nat Commun，2014，5：4306.
[10] Nasiri MJ，Darban-Sarokhalil D，Fooladi AA，et al. katG Ser315 and rpoB 81bp hotspot region substitutions：reliability for detection of drug-resistant strains of Mycobacterium tuberculosis [J]. J Glob Antimicrob Resist，2016， 5：92-93.
[11] Jamieson FB，Guthrie JL，Neemuchwala A，et al. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis [J]. J Clin Microbiol，2014， 52（6）：2157-2162.
[12] Otchere ID，Asante-Poku A，Osei-Wusu S，et al. Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains：A prospective study in two distant regions of Ghana [J]. Tuberculosis（Edinb），2016，99：147-154.
[13] Torres JN，Paul LV，Rodwell TC，et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates [J]. Emerg Microbes Infect，2015，4（7）：e42.
[14] Cohen KA，Bishai WR，Pym AS. Molecular basis of drug resistance in Mycobacterium tuberculosis [J]. Microbiol Spectr，2014，2（3）：1-16.
[15] Ando H，Miyoshi-Akiyama T，Watanabe S，et al. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis [J]. Mol Microbiol，2014，91（3）：538-547．
[16] Philley JV，Griffith DE. Treatment of slowly growing Mycobacteria [J]. Clin Chest Med，2015，36：79-90.
[17] Brossier F，Sougakoff W，Bernard C，et al. Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France [J]. Antimicrob Agents Chemother，2015，59（8）：4800-4808.
[18] Gu Y，Yu X，Jiang G，et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA，rpsA，and panD gene mutations [J]. Diagn Microbiol Infect Dis，2016，84：207-211.
[19] Zhang S，Chen J，Shi W，et al. Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis [J]. Emerg Microbes Infect，2017，6（2）：e8.
[20] Smittipat N，Juthayothin T，Billamas P，et al. Mutations in rrs，rpsL and gidB in streptomycin-resistant Mycobacterium tuberculosis isolates from Thailand [J]. J Glob Antimicrob Resist，2016，4：5-10.
[21] Sowajassatakul A，Prammananan T，Chaiprasert A，et al. Molecular characterization of amikacin， kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand [J]. BMC Microbiol，2014，14：165.
[22] Gikalo MB，Nosova EY，Krylova LY，et al. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region [J]. J Antimicrob Chemother，2012，67（9）：2107-2109.
[23] Via LE，Cho SN，Hwang S，et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosisisolates from South Korean patients with drug-resistant tuberculosis [J]. J Clin Microbiol，2010，48（2），402-411.
[24] Sirgel FA，Warren RM，Streicher EM，et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis [J]. J Antimicrob Chemother，2012，67（5）：1088-1093.
[25] 李超，李桂莲，罗巧，等.结核分枝杆菌对环丝氨酸耐药分子特征的初步研究[J].中华流行病学杂志，2017，38（2）：230-243.
[26] Sotgiu G，Pontali E，Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis： available evidence and future scenarios [J]. Eur Respir J，2015，45（1）：25-29.
[27] Beckert P，Hillemann D，Kohl TA，et al. rplC T460C identified as a dominant mutation in linezolid resistant Mycobacterium tuberculosis strains [J]. Antimicrob Agents Chemother，2012，56（5）：2743-2745.
[28] World Health Organization. WHO treatment guidelines for drugresistant tuberculosis（2016 update）[R]. Geneva：World Health Organization，2016.
[29] Xu J，Wang B，Hu M，et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis [J]. Antimicrob Agents Chemother，2017，61（6）：e00239-17.
[30] Zhang S，Chen J，Cui P，et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis [J]. J Antimicrob Chemother，2015，70（9）：2507-2510.
[31] Huang Z，Qin C，Du J，et al. Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China：a prospective multicenter study [J]. J Antimicrob Chemother，2015， 70（2）：456-462.
[32] World Health Organization. Strategic and Technical Advisory Group for tuberculosis （STAG-TB）[R]. Geneva：WHO，2007.
[33] Cui Z，Wang J，Zhu C，et al. Evaluation of a novel biphasic culture medium for recovery of mycobacteria：a multi-center study [J]. PLoS One，2012，7（4）：e36331.
[34] 李妍，张天华，鲜小萍，等．Xpert MTB/RIF检测技术诊断肺结核和肺外结核的价值[J].中国防痨杂志，2015， 37（6）：586-589.
[35] Chakravorty S，Simmons AM，Rowneki M. The New Xpert MTB/RIF Ultra：Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing [J]. MBio，2017，8（4）：e00812-17.
[36] Bahr NC，Nuwagira E，Evans EE. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults：a prospective cohort study [J]. Lancet Infect Dis，2018，18（1）：68-75.
[37] 胡春梅，郭晶，严虹，等.荧光定量PCR探针熔解曲线法在结核分枝杆菌耐药基因检测中的应用[J].中国防痨杂志，2016，38（1）：38-41.
[38] 严虹，施旭东，胡春梅，等.探针熔解曲线法快速检测结核分枝杆菌利福平、异烟肼、乙胺丁醇及链霉素耐药突变[J].临床检验杂志，2015，33（10）：729-733.
[39] Yacoob FL，Philomina Jose B，Karunakaran Lelitha SD，et al. Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India [J]. J Pathog，2016，2016：6235618.
[40] K?觟ser CU，Javid B，Liddell K，et al. Drug-resistance mechanisms and tuberculosis drugs [J]. Lancet，2015，385（9965）：305-307.
[41] Lanzas F，Ioerger TR，Shah H，et al. First evaluation of GenoType MTBDRplus 2.0 performed directly on respiratory specimens in Central America [J]. J Clin Microbiol，2016，54（10）：2498-2502.
[42] Lu W，Chen C，Shao Y，et al. Evaluation of biochip system in determing Isoniazid and rifampin resistances of Mycobacterium tuberculosis in sputum samples [J]. PLoS One，2012，7（12）：e52953.
[43] Phelan J，O′Sullivan DM，Machado D，et al. The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs [J]. Genome Med，2016，8（1）：132.
[44] Jeanes C，O′Grady J. Diagnosing tuberculosis in the 21st century-Dawn of a genomics revolution [J]. Int J Mycobacteriol，2016，5（4）：384-391.